Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure
German drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication Jardiance (empagliflozin) in India, for additional indication to reduce the risk of heart failure in adults.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Germany Health | Heart | Heart Failure | India Health | Jardiance | Pharmaceuticals